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The short splice variant of the basic helix-loop-helix Per-Arnt-Sim transcription factor Singleminded-2,
SIM2s, has been implicated in development and is frequently lost or reduced in primary breast tumors. Here,
we show that loss of Sim2s causes aberrant mouse mammary gland ductal development with features sugges-
tive of malignant transformation, including increased proliferation, loss of polarity, down-regulation of E-
cadherin, and invasion of the surrounding stroma. Additionally, knockdown of SIM2s in MCF-7 breast cancer
cells contributed to an epithelial-mesenchymal transition (EMT) and increased tumorigenesis. In both
Sim2/ mammary glands and SIM2s-depleted MCF7 cells, these changes were associated with increased
SLUG and MMP2 levels. SIM2s protein was detectable on the SLUG promoter, and overexpression of SIM2s
repressed expression from a SLUG-controlled reporter in a dose-dependent manner. To our knowledge, SIM2s
is the first protein shown to bind and repress the SLUG promoter, providing a plausible explanation for the
development role and breast tumor-suppressive activity of SIM2s. Together, our results suggest that SIM2s is
a key regulator of mammary-ductal development and that loss of SIM2s expression is associated with an
invasive, EMT-like phenotype.
Branching morphogenesis is a tightly regulated, complex
process that contributes to lung, kidney, central nervous system
(CNS), and mammary gland development. In the developing
mammary gland, cell division and migration are confined to the
cap cell layer at the leading edges of terminal end buds
(TEBs), which invade the surrounding fat pad, leaving behind
the basic mammary-ductal tree (37, 38). Cells trailing TEBs
stop dividing, form a hollow tube through an apoptotic mech-
anism, and differentiate into polarized luminal epithelial cells.
Proper regulation of mammary epithelium- and stroma-de-
rived signals is paramount to ensuring correct temporal and
spatial control of these processes, and disruption of epithelial-
stromal communication is associated with breast cancer initi-
ation and progression. While branching morphogenesis differs
between tissues, there are a large number of shared molecular
mechanisms, suggesting that a “branching module” of signaling
pathways exists (5).
In the developing Drosophila CNS, specification of the CNS
midline is dependent upon the basic helix-loop-helix Per-Arnt-
Sim transcription factor single-minded (sim), which serves as
the master regulator of midline differentiation. Singleminded-2
(SIM2) is one of two vertebrate orthologs of Drosophila sim
protein, but it differs in functioning as a transcriptional repres-
sor (10, 24, 30). SIM2 was initially identified by positional
cloning around the Down syndrome critical region of chromo-
some 21 and is believed to contribute to many of the physio-
logical abnormalities associated with trisomy 21 (4). Sim2 plays
an important role in development, as Sim2 null mice die
shortly after birth due to multiple abnormalities, including cleft
palate, improper diaphragm development, and rib defects (12,
33). The molecular mechanisms controlling these processes are
complex and involve the concerted actions of many factors,
including transforming growth factor , epidermal growth fac-
tor receptor, and matrix metalloproteases (MMPs) (3, 23, 36).
These pathways are also known to contribute to pathological
conditions, including tumor progression and metastasis. The
fact that Sim2/ mice have these defects suggests that Sim2
regulates pathways involved in growth and motility.
During morphogenesis, epithelial-to-mesenchymal transi-
tions (EMTs) play an important role in regulating cellular
migration and establishment of new tissue types (34). Similar
transitions commonly occur during cancer progression and me-
tastasis, leading to increased tumor cell motility and invasion.
Loss of the cell-cell adhesion molecule E-cadherin is central to
EMT, and invasive lobular carcinomas of the breast often
exhibit loss of E-cadherin expression or function (17, 21). Sim-
ilar to fate determination in the Drosophila midline, induction
of EMT by the transcription factors SNAIL, SLUG, and
TWIST is dependent upon their abilities to silence expression
from the E-cadherin promoter; however, the molecular mech-
anisms acting upstream of these factors are not well charac-
terized (17, 21).
Previously, we showed that human breast luminal epithelial
cells primarily express the short splice variant of SIM2, SIM2s,
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which acts as a breast tumor suppressor (20). In the present
study, we report that loss of Sim2s in mouse mammary epithe-
lium leads to increased proliferation, loss of E-cadherin, and
invasion into the surrounding stroma. Furthermore, vector-
based short hairpin RNA (shRNA) silencing of SIM2s in the
human breast cancer cell line MCF-7 promoted EMT and
increased tumorigenesis. Concomitant with this phenotype,
loss of SIM2s resulted in dysregulation of MMP2 and SLUG
expression. These results suggest that SIM2s plays a key role in
controlling normal EMT processes involved in mammary gland
development and that loss of SIM2s promotes pathological
EMT events associated with tumor progression.
MATERIALS AND METHODS
Cell culture. The cell lines used in these studies were obtained from the
American Type Culture Collection and were maintained as recommended.
HEK-293T Ampho-Phoenix packaging cells were obtained with permission from
Gary Nolan at Stanford University.
Animals. Female C57BL/6J and nude mice were from Jackson Laboratories.
The Sim2 knockout mice were obtained from a private collection at Jackson
Laboratories with permission from Michael Shamblott at Johns Hopkins Uni-
versity. All animals were housed three per cage under a standard 12-hour pho-
toperiod. The animals were provided with access to food and water ad libitum.
All procedures were approved by the University Laboratory Animal Care Com-
mittee at Texas A&M University.
Generation of stable shRNA-expressing cell lines. pSilencer U6 retro 5.1
expression vectors (Ambion, Austin, TX) bearing either one of three SIM2-
specific or a nonspecific scrambled control (SCR) insert were packaged into virus
using Phenix HEK293-Ampho packaging cells and used to transduce MCF-7
cells according to the manufacturer’s protocol. Pooled populations of the
two most effective of the three SIM2-specific constructs, SIM2i3116 (SIM2i) and
SIM2i114478 (SIM2i2), were confirmed to decrease SIM2 protein levels,
and SIM2i was used for all subsequent studies. A third SIM2-targeting sequence,
SIM2i114477 (SIM2i3), was also analyzed but failed to decrease SIM2 expression.
Cells were selected in the presence of 2 g/ml puromycin based on kill curves of
mock-infected MCF-7 cells. The MCF-7 shRNA cell lines analyzed were pooled
populations, not selected single-cell clones.
Invasion assays. Invasion was measured using control and Matrigel-coated
invasion chambers (Falcon BD, Franklin Lakes, NJ). A total of 12,500 cells were
seeded in serum-free Dulbecco’s modified Eagle’s medium (DMEM) in the
upper chamber, with serum-containing medium in the lower chamber as a che-
moattractant. After 20 h at 37°C, cells were scraped from the upper chamber with
a cotton swab, and the undersides of the membranes were fixed in 100% MeOH,
stained with DAPI (4,6-diamidino-2-phenylindole), and counted. The percent
invasion was calculated according to the manufacturer’s instructions.
Real-time RT-PCR. RNA isolation and real-time reverse transcription (RT)-
PCR were performed as described previously (20). Primer sequences are listed in
Table S1 in the supplemental material. Product specificity was examined by
dissociation curve analysis.
Immunoblotting and zymography. Cells were lysed on ice in RIPA buffer
(phosphate-buffered saline [PBS] containing 1% Igepal CA630, 0.5% sodium
deoxycholate, and 0.1% sodium dodecyl sulfate) containing protease inhibitors
and 20 M MG132. The lysates were cleared by centrifugation, and 50 g of total
protein was separated on sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis gels and transferred to polyvinylidene difluoride membranes. Primary
antibodies and conditions are listed in Table S2 in the supplemental material. All
secondary antibodies were used at a 1:5,000 dilution. Immunoblots were visual-
ized with an ECL kit (Amersham). To determine MMP activity, conditioned
medium from treated cells was concentrated 20-fold using Centricon 10 spin
concentrators (Amicon). Equal amounts of protein were mixed with Laemmli
sample buffer without reducing agents, incubated for 15 min at 37°C, and sepa-
rated on 8% polyacrylamide slab gels containing 1 mg/ml gelatin or 0.05% casein.
Following electrophoresis, the gels were placed in 2.5% Triton X-100 for 30 min
and then incubated at 37°C in 50 mM Tris-HCl, pH 7.4, containing 5 mM CaCl2
for 18 h. MMP activity was visualized by Coomassie blue staining.
Immunofluorescence analysis and phase-contrast microscopy. Primary anti-
bodies and conditions for immunostaining are listed in Table S2 in the supple-
mental material. Monolayers grown on glass coverslips were prepared for im-
munofluorescence analysis by washing them twice in PBS, followed by fixation
with 3.8% paraformaldehyde, permeabilization in 0.5% Triton X-100, and two
rinses in 100 mM glycine. Blocking was performed for 2 h in PBS containing 5%
bovine serum albumin, and primary antibodies were applied overnight in block-
ing solution. Mammary gland and xenograft tumor sections on Superfrost plus
microscope slides were baked at 60°C for 30 min in an upright position and then
rehydrated by sequential washes in xylene and a series of graded ethanol washes.
Antigen retrieval was performed for 15 min at 98°C in 0.01 mol/liter sodium
citrate buffer, pH 6.0, in a microwave oven. When appropriate, sections were
incubated in 3% hydrogen peroxide for 6 min to block endogenous peroxidase
activity. After a 45-min block in 10% serum, the sections were incubated with the
primary antibody for 2 h at room temperature or overnight at 4°C. Secondary
detection was performed with a fluorescent secondary antibody or the appropri-
ate biotinylated secondary antibody, a Vectastain ABC elite kit, and 3,3-diami-
nobenzidine (Vector Laboratories, Burlingame, CA). DAPI, fluorescent Alexa
Fluor-conjugated secondary antibodies, and phalloidin were purchased from
Molecular Probes and applied according to the manufacturer’s instructions. For
phase-contrast analysis, cells were grown on glass coverslips and visualized in
10% DMEM. All microscopic images were taken with a Zeiss Axioplan 2 mi-
croscope (Carl Zeiss, Thornwood, NY) fitted with an Axiocam high-resolution
digital camera and using Axiovision 4.1 software.
Nude-mouse xenograft tumor studies. Either Scr or SIM2i MCF-7 cells (1 
107) suspended in 100 l of DMEM-50% Matrigel (BD Biosciences) were
injected into each flank of nude mice. Tumor size was measured with calipers on
days 3, 10, 14, and 17. The mice were injected with bromodeoxyuridine (BrdU)
(Amersham) 2 h prior to sacrifice on day 17. Tumors and tissues were removed,
photographed, weighed, and frozen for subsequent RNA and protein extraction.
Half of the tissue was fixed in 4% paraformaldehyde, embedded in paraffin, and
sectioned.
Chromatin immunoprecipitation (ChIP) assays and transient transfections.
Transient-transfection experiments and ChIP assays were performed as de-
scribed previously (22). Primer sequences are presented in Table S1 in the
supplemental material.
Mammary gland transplantation and whole-mount analysis. Mammary tissue
from day 1 pups was dissected out and transferred into the cleared number 4
mammary fat of nude mice. After 8 weeks, the transplants were removed, fixed
in 10% neutral-buffered formalin, and analyzed by whole-mount analysis. He-
matoxylin and eosin (HE) and trichrome staining of sections was performed by
the Department of Integrated Biosciences Histology Core Facility at Texas
A&M University.
Statistical analyses. Statistical analyses for these studies were performed using
Student’s t test. The errors bars in graphs represent standard errors of the mean
(SEM) in all cases.
RESULTS
Sim2s expression is spatially and temporally regulated in
the developing mouse mammary gland. Mammary gland de-
velopment is regulated through a branching-morphogenesis
mechanism driven by the growth of TEBs, which are charac-
terized by a highly proliferative and invasive “cap cell” layer
that divides and invades the surrounding stroma. TEBs are
controlled by a complex balance of stroma- and epithelium-
derived signals that guide TEB growth, ensuring orderly de-
velopment of a mammary-ductal structure. The developmental
defects observed in Sim2/ mice, coupled with its antitumori-
genic effects in breast cancer-derived cell lines (20), suggest a
possible developmental role for Sim2 in the mammary gland.
Indeed, Western blot analysis found that, similar to the human
breast (20), Sim2s is the predominant Sim2 isoform expressed
in 15-week-old virgin-mouse mammary glands (Fig. 1A),
whereas skeletal muscle expressed both the short and long
isoforms (22). In addition, Sim2s was detectible in ductal epi-
thelial cells (Fig. 1B), supporting a role for Sim2s in mammary
gland development.
Aberrant ductal development and hyperplasia in Sim2/
mouse mammary glands. Since Sim2/ mice die shortly after
birth (12, 33), wild-type (WT) and Sim2/ mammary buds from
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day 1 neonates were rescued and transplanted contralaterally into
cleared inguinal mammary fat pads of nude mice. After 8 weeks,
WT and Sim2/ outgrowths were removed and analyzed. Gross
observation of whole-mount stained mammary outgrowths high-
lighted subtle differences in the morphology of Sim2/ ducts.
Most notably, Sim2/ ducts appeared to have increased alveolar
budding reminiscent of an increase in differentiation (Fig. 1C).
However, HE-stained sections of WT and Sim2/ mammary
outgrowths revealed that Sim2/ ducts had failed to hollow and
that the bud-like structures were comprised of disorganized epi-
thelial cells (Fig. 1D). Furthermore, Masson’s trichrome staining
revealed that the basement and interstitial membranes surround-
ing Sim2/ glands appeared to be disrupted, with noticeable
regions of collagen depletion (Fig. 1E, left). Upon closer exami-
FIG. 1. Sim2 is required for normal mammary-ductal development in mice. Mammary buds were removed from 1-day-old WT and Sim2/
neonates and transplanted contralaterally into the cleared inguinal mammary fat pads of nude mice. Following 8 weeks of outgrowth, the mammary
glands were removed and fixed for whole-mount staining and sectioning. (A) Western blot analysis of mammary glands from 15-week-old virgin
mice and skeletal muscle using a pan-Sim2-specific antibody showing that Sim2s is expressed in the developing mouse mammary gland, whereas
skeletal muscles express both isoforms. -Act, actin. (B) Immunohistochemical analyses using antibodies specific to the Sim2s isoform and a
pan-Sim2-specific antibody showing Sim2s expression in luminal epithelial cells. (C) Representative images of hematoxylin-stained whole mounts
of WT and Sim2/ mammary outgrowths showing bud-like structures on Sim2/ mammary ducts. (D) HE-stained sections from WT (top) and
Sim2/ (bottom) mammary outgrowths showing filled ducts (bottom left) and a detailed image of budding structures (bottom right) in Sim2/
mammary glands. (E) Representative images of Masson’s trichrome-stained mammary sections from WT (top) and Sim2/ (bottom) mammary
glands. The arrows indicate areas of collagen depletion and apparent Sim2/ epithelial cell invasion into the surrounding stroma. (F) Ki-67-
stained sections of WT (top) and Sim2/ (bottom) mammary glands indicating that Sim2 loss significantly increases cellular proliferation.
Quantification of Ki-67-positive cells (right) suggested that Sim2/ glands experience a greater-than-fivefold increase in cell division. The data
are represented as the mean plus SEM; * indicates that P was 0.05. (G) Immunofluorescence staining for keratin 14 (red; left colum) and
aquaporin 5 (green; right column) in WT (top row) and Sim2/ (bottom row) mammary glands. Note that the “budding” Sim2/ epithelial cells
are not surrounded by a keratin 14-positive myoepithelial cell layer (arrows), suggesting they are actively invading the surrounding stroma.
Aquaporin 5 staining (right) highlights the compromised polarity observed in Sim2/ mammary epithelium. Bars 	 100 m.
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nation, Sim2/ epithelial cells could be seen breaking through
these membranes and migrating into the surrounding stroma
(Fig. 1E, right). The filled ducts observed in Sim2/ glands were
likely due to increased proliferation, as Sim2/ mammary epi-
thelial cells displayed a fivefold increase in staining for the pro-
liferation marker Ki-67 (Fig. 1F), and terminal deoxynucleotidyl-
transferase-mediated dUTP-biotin nick end labeling analyses did
not show significant differences in apoptosis (data not shown).
Keratin 14 staining indicated that the myoepithelial cell layer of
Sim2/ ducts was intact, while Sim2/ epithelial cells appeared
to have invaded the surrounding stroma (Fig. 1G, left). This
phenomenon is distinct from normal side branching and is con-
sistent with a more aggressive phenotype. Staining for aquaporin
5, an apical epithelial cell marker, suggested that the lumens
occasionally seen in larger Sim2/ ducts were lined primarily
with nonpolarized cells, implying that Sim2 loss has a significant
impact on mammary epithelial organization (Fig. 1H, right).
Silencing SIM2s induces EMT in MCF-7 cells. Previously,
we showed that SIM2s expression is lost in human breast tu-
mors and correlates inversely with breast cancer cell invasive-
FIG. 2. Silencing of SIM2s alters cellular morphology, increases invasive potential, and causes EMT in MCF-7 cells. (A) Structure of the SIM2s
mRNA transcript showing regions targeted by shRNA constructs. Exons are indicated by numbered boxes. The dotted line indicates splicing that
generates the full-length SIM2 transcript. (B) Infection of MCF-7 cells with shRNA construct SIM2i or SIM2i2 resulted in decreased SIM2s protein
levels in comparison to a nonspecific SCR shRNA construct. Down-regulation of SIM2s expression by the SIM2i3 construct could not be confirmed
(data not shown). (C) Down-regulation of SIM2s significantly increased MCF-7 cell invasive ability. The data are represented as the mean plus
SEM; * indicates that P was 0.05. (D) Phaloidin-stained control (SCR) and SIM2i MCF-7 cells indicated that decreased SIM2s expression
correlated with alterations in cellular morphology. SIM2i cells showed a loss of the cobblestone morphology seen in SCR MCF-7 cells and
acquisition of a more spindly appearance. (E) Decreased SIM2s expression leads to loss of E-cadherin and gain of vimentin. (F) Immunofluo-
rescent staining of control (SCR) (top) and SIM2i (bottom) MCF-7 cells showing that loss of SIM2s expression results in loss of the epithelial
markers E-cadherin and keratin 18 and gain of the mesenchymal markers N-cadherin and vimentin and thus a switch from an epithelial to a more
mesenchymal phenotype. In addition, increased nuclear staining of phosphorylated -catenin, a phenomenon recently associated with poor breast
cancer prognosis, can be seen in SIM2i cells. (G) Western blot and real-time quantitative PCR analyses of SCR and SIM2i MCF-7 cells for
expression of keratin 18 (K18), E-cadherin, N-cadherin, and vimentin mRNAs. The data were obtained from three wells per group and analyzed
by the 

CT method and are expressed as the average difference plus SEM; *, P  0.05. Combined with the altered cell morphology and gain
of invasive potential, these data suggest that loss of SIM2s expression in MCF-7 cells induces an EMT.
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ness (20). Reintroduction of SIM2s into highly invasive cancer
cells resulted in decreased proliferation, migration, and inva-
sion. To further delineate the role of SIM2s in cancer progres-
sion, MCF-7 cells were transduced with either a nonspecific
SCR shRNA retroviral construct or one of three SIM2-specific
shRNA constructs targeting different regions of the SIM2
mRNA (SIM2i2, SIM2i, and SIM2i3) (Fig. 2A). Significant
reduction in SIM2s protein was observed in the SIM2i2 and
SIM2i cell lines (Fig. 2B), but not in SIM2i3 cells (data not
shown). In three independent infections, pooled populations of
MCF-7 SIM2i and SIM2i2 cells showed significantly enhanced
invasive abilities (Fig. 2C) and underwent a morphological
change from the cobblestone epithelial shape typical of MCF-7
cells to a spindly mesenchymal-cell-like morphology (Fig. 2D),
suggesting that loss of SIM2s expression had induced EMT.
Indeed, Western blots (Fig. 2E) confirmed that SIM2i and
SIM2i2 cells lost E-cadherin and increased expression of N-
cadherin and vimentin.
To confirm that the morphological and biochemical changes
observed with the loss of SIM2s were indeed an EMT, we
characterized further the SIM2i MCF-7 cell line to assay for
expression of additional epithelial and mesenchymal cell mark-
ers. Immunofluorescence (Fig. 2F) showed that SIM2i cells
lost expression of keratin 18 and E-cadherin and gained N-
cadherin and vimentin. Although SIM2i MCF-7 cells express
mesenchymal markers and do not express E-cadherin, in-
creased nuclear accumulation of -catenin was not detectable
by antibodies against the active, nonphosphorylated (S37 and
T41) form (data not shown). There was, however, a marked
increase in nuclear accumulation of the phospho-S33, -S37,
and -T41 forms of -catenin (Fig. 2F), a phenomenon recently
shown to be associated with poor prognosis in aggressive breast
carcinomas (26). Changes in SIM2s protein levels were accom-
panied by dramatic decreases in keratin 18 and E-cadherin
message and increased N-cadherin and vimentin mRNAs, as
measured by real-time RT-PCR (Fig. 2G). Together, these
data indicate that loss of SIM2s in MCF-7 cells results in a
morphological, functional, and biochemical switch from an ep-
ithelial to a more mesenchymal-like phenotype.
SIM2i MCF-7 cells form rapidly growing estrogen receptor
 (ER) tumors in nude mice. To assess the tumorigenic
effects of SIM2s loss, we compared the tumor-forming ability
of SIM2i cells to that of control cells using a nude-mouse
xenograft assay. SIM2i cells rapidly developed into tumors that
were three times larger than controls by day 10 (Fig. 3A).
SIM2i cell-derived tumors maintained this size advantage
throughout the experiment and were sixfold larger than SCR-
derived tumors, with an average weight sevenfold higher than
that of control tumors at the conclusion of the study 17 days
after injection (Fig. 3B). SIM2i tumors appeared to be more
vascularized than control tumors (Fig. 3C), an observation that
was confirmed by increased CD31 and vascular endothelial
growth factor immunoreactivity (Fig. 3D). Quantification of
BrdU-positive cells from xenograft tumor sections showed a
35-fold increase in SIM2i cell proliferation (Fig. 3E) (SCR 	
1.1%  0.543%; SIM2i 	 35.1%  2.24%), suggesting a link
between increased vascularity, cell proliferation, and tumor
growth in SIM2i-derived tumors. This sizable increase in pro-
liferation was unexpected, as the SIM2i cells do not proliferate
more rapidly than the SCR control MCF-7 cell line in vitro
(data not shown). Similar to our in vitro studies (Fig. 2),
SIM2i-derived tumors displayed signs of EMT with decreased
E-cadherin and increased vimentin staining (Fig. 3D).
Normally, tumor development in the MCF-7 xenograft
model requires exogenous estrogen to sustain growth. There-
fore, we were surprised to see tumors develop so rapidly in the
absence of estrogen. The accelerated rate of SIM2i tumor
growth coupled with the apparent estrogen-independent na-
ture of this growth prompted us to look at ER expression.
Indeed, ER was undetectable in SIM2i-derived tumors by
immunohistochemistry (Fig. 3D) or in SIM2i MCF-7 cells by
either real-time RT-PCR (Fig. 4A) or Western blotting (Fig.
4B). Furthermore, SIM2i cells no longer responded to estro-
gen treatment as measured by estrogen-induced proliferation
(data not shown) and induction of the estrogen-responsive
genes PR and PS2 (Fig. 4C and D). The striking increase in
SIM2i MCF-7 cell tumorigenesis confirms that loss of SIM2
has functional consequences in vivo and provides further evi-
dence that SIM2s may represent an important hurdle to breast
cancer progression.
SIM2s represses MMP2 expression and activity. In previous
studies utilizing MDA-MB-435 cells, we reported that MMP3
is a direct target of SIM2s-mediated transcriptional repression
(20). Therefore, we hypothesized that up-regulation of MMPs
may contribute to the aggressive, invasive phenotype observed
in SIM2s-compromised cells. Expression of several MMPs, and
related factors, was analyzed in SCR and SIM2i cells by real-
time PCR. To our surprise, we found MMP2 to be up-regu-
lated 4,500-fold in SIM2i cells, while MMP3 mRNA expres-
sion was not significantly altered (Fig. 5A). MMP14 and
TIMP2, which are required for MMP2 activation, were also
up-regulated approximately six- and sevenfold, respectively, in
SIM2i cells (Fig. 5A). The MMP2 mRNA increase observed in
SIM2i cells was corroborated at the protein and activity levels,
while MMP3 protein expression and activity were unchanged
(Fig. 5B). In addition, MMP2 levels were markedly elevated in
xenograft tumor sections derived from SIM2i cells in compar-
ison to those derived from control cells (Fig. 5C), confirming
that loss of SIM2s led to increased MMP2 expression. In-
creased MMP2 expression was attributable to derepression of
the MMP2 promoter, as expression of an MMP2-controlled
luciferase reporter was significantly higher in SIM2i cells (Fig.
5D). Cotransfection of the MMP2 reporter and increasing
amounts of SIM2s expression vector in MCF-7 cells resulted in
dose-dependent inhibition of luciferase activity (Fig. 5E).
While we did not see the expected increase in MMP3 secretion
in SIM2i MCF-7 cells (20), we hypothesize that this may be due
to intrinsic differences between MDA-MB-435 and MCF-7
cells. Breast cancer cell lines and primary breast tumors often
have dramatically different molecular signatures. Therefore,
differences in MMP regulation between the cell types following
modulation of SIM2s expression are probably due to inherent,
as yet uncharacterized, molecular processes.
SIM2s participates in the maintenance of E-cadherin ex-
pression via repression of Slug. The loss of E-cadherin and
keratin 18 with gain of N-cadherin and vimentin expression in
SIM2i MCF-7 cells suggests that SIM2s may regulate factors
involved in EMT. Members of the SNAIL family of transcrip-
tion factors have been implicated in regulation of both normal
and pathological EMT events (8, 27, 28, 41). During cancer
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progression, increased SNAIL and SLUG binding to E-box
regulatory DNA elements causes transcriptional repression of
E-cadherin, which contributes to transformation, angiogenesis,
and EMT (8, 27, 28, 41). To determine if members of the
SNAIL family are involved in the EMT induced by SIM2s loss,
SCR and SIM2i cells were analyzed for SNAIL and SLUG
mRNA levels by real-time RT-PCR. SNAIL mRNA levels
were not significantly affected by SIM2 loss in MCF-7 cells
(Fig. 6A). In contrast, SLUG expression was up-regulated
more than 250-fold in SIM2i cells (Fig. 6A), which corre-
sponded to an increase in SLUG protein levels as determined
by Western analysis (Fig. 6B).
Since SIM2s functions as a transcriptional repressor (18, 20,
25), we hypothesized that SIM2s directly inhibits SLUG ex-
pression at the promoter level. A luciferase reporter under the
control of the human SLUG promoter was transfected into
SCR and SIM2i MCF7 cells and analyzed for activity. In SIM2i
MCF-7 cells, basal reporter expression was increased 10-fold
over control cells (Fig. 6C). In addition, we observed concen-
tration-dependent repression of SLUG promoter-controlled
gene expression with increasing amounts of SIM2s in MCF-7
cells (Fig. 6D). The human SLUG promoter contains multiple
putative regulatory elements, including E-boxes, xenobiotic re-
sponse elements (XREs), and central midline element (CME)
core sequences (Fig. 6E). Using an antibody to SIM2s in ChIP
analyses, we found that SIM2s binds a region of the SLUG
promoter containing the CME and two XRE core sequences in
SCR, but not SIM2i, MCF-7 cells (Fig. 6E). SIM2s was unable
to bind a region of the E-cadherin promoter containing E-
boxes that were targeted by SNAIL protein family members;
however, increased binding of SLUG to this region was appar-
ent in SIM2i MCF-7 cells (Fig. 6F). As the ChIP primers used
in our study flank the putative CME and two XREs, it seems
likely that SIM2s-mediated repression of SLUG involves bind-
ing of SIM2s to one or more of these elements. Taken to-
gether, these data suggest that loss of SIM2s leads to derepres-
sion of SLUG expression and increased SLUG binding to the
E-cadherin promoter, where it potentially plays a role in re-
pressing E-cadherin transcription.
Sim2/ mammary glands display hallmarks of EMT. Our
initial analyses of Sim2/ mammary outgrowths, coupled with
in vitro MCF-7 cell studies, strongly suggest that loss of Sim2s
FIG. 3. Loss of SIM2s enhances in vivo tumorigenicity. Control (SCR) and SIM2i MCF-7 cells were mixed with growth factor-reduced Matrigel
and injected into the flanks of nude mice to determine the effects of SIM2s loss on tumor growth. The mice were palpated, and tumors were
measured over a period of 17 days. On the day of harvest, the mice were injected with BrdU and sacrificed 2 hours later. The tumors were removed,
weighed, photographed, and fixed in 4% paraformaldehyde for subsequent analyses. (A) SIM2i MCF-7 cells rapidly formed tumors that were
significantly larger than control tumors by 10 days postinjection. This trend continued throughout the study. The data are represented as means
plus SEM; * indicates that P was 0.05; ** indicates that P was 0.005. (B) After 17 days, the tumors were removed and weighed. The average
weight of SIM2i-derived tumors was significantly higher than that of control tumors. The data are represented as means plus SEM; ** indicates
that P was 0.005. (C) Representative tumors from SCR and SIM2i MCF-7 cells injected into nude-mouse flanks. Note the apparent increased
vascularization in SIM2i-derived tumors. (D) Sections from SCR- and SIM2i-derived tumors were analyzed for expression of various markers by
immunostaining and immunofluorescence. Increased vascularization of SIM2i-derived tumors is supported by increased CD31 and vascular
endothelial growth factor (VEGF) protein levels seen in sections of xenograft tumors. BrdU staining indicated that SIM2i tumor cells divide at
a significantly higher rate than SCR control tumors. As was seen in vitro, loss of SIM2s expression coincided with loss of E-cadherin and gain of
vimentin staining in SIM2i-derived tumors. The apparent aggressiveness of SIM2i-derived tumors, and their lack of an exogenous estrogen
requirement, corresponded with loss of ER expression. Bar 	 100 m.
VOL. 28, 2008 MECHANISTIC BASIS OF TUMOR SUPPRESSION BY SIM2s 1941
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
expression leads to an EMT. To confirm this in vivo, Sim2/
mammary sections were analyzed for various epithelial and
mesenchymal markers. Robust E-cadherin staining was ob-
served throughout WT mammary epithelium but was totally
absent in Sim2/ glands (Fig. 7A). Not surprisingly, the in-
creased invasive ability of Sim2/ epithelial cells was associ-
ated with increased Mmp2 protein levels (Fig. 7A). These
observations strongly suggest that an EMT similar to that ob-
served in SIM2i MCF-7 cells had occurred in Sim2/ glands.
This was further supported by increased nuclear accumulation
of -catenin in Sim2/ ductal epithelium (Fig. 7A). Consis-
tent with our model that SIM2s-mediated repression of SLUG
suppresses EMT, we found increased Slug staining in Sim2/
glands (Fig. 7A). Taken together, these data show that loss of
FIG. 4. Loss of ER expression and estrogen responsiveness in SIM2i MCF-7 cells. (A) Quantitative real-time PCR analysis of control (SCR)
and SIM2i MCF-7 cells for ER RNA. The data were obtained from three wells per group and analyzed by the 

CT method and are expressed
as the average difference plus SEM; *, P 0.05. (B) Western analysis of SCR and SIM2i MCF-7 cells corroborated the mRNA data and confirmed
that loss of SIM2s expression results in loss of R. -Actn, -actin. (C and D) Quantitative real-time PCR analysis of vehicle (DMSO)- and
estradiol (E2)-treated SCR and SIM2i MCF-7 cells indicated that estrogen responsiveness is lost in SIM2i cells. Both progesterone receptor
(C) and PS2 (D) mRNA induction following estradiol treatment was lost in SIM2i cells. The data are presented as the average difference plus SEM;
*, P  0.05.
FIG. 5. SIM2s Inhibits MMP2 expression and activation. (A) Expression of MMP2, MMP14, and TIMP2, but not MMP3, was increased in
SIM2i MCF-7 cells in comparison to control cells (SCR). (B) Increased MMP2 mRNA corresponded to increased MMP2 protein (top) and activity
(bottom) in SIM2i MCF-7 cells with no effect on MMP3 protein or activity. (C) Immunostaining of SCR- and SIM2i-derived tumor sections
indicated that MMP2 expression was significantly elevated in SIM2i-derived tumors. Bar 	 100 m. (D) Basal expression of an MMP2
promoter-controlled reporter was significantly elevated in SIM2i cells, suggesting that SIM2s can directly repress MMP2 expression. (E) This
hypothesis is supported by the dose-dependent effects of SIM2s on repression of an MMP2-controlled reporter. The data are represented as means
plus SEM; * indicates that P was 0.05; ** indicates that P was 0.005.
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Sim2s during mouse mammary gland ductal development re-
sults in Slug up-regulation, loss of epithelial cell characteristics,
increased Mmp2 expression, and invasion of the surrounding
stroma, reminiscent of an EMT (Fig. 7B).
DISCUSSION
Based on the role of sim in Drosophila CNS development (6,
7), the developmental defects observed in Sim2/ mice (12,
33), and our previous studies showing that SIM2s is expressed
in human breast luminal epithelial cells and is down-regulated
in breast cancers (20), we hypothesized that Sim2 contributes
to normal mammary gland development. Indeed, we found
that Sim2s is the primary Sim2 isoform expressed in the devel-
oping mouse mammary gland and that loss of Sim2s results in
abnormal mammary-ductal morphology manifested by failure
of the ducts to hollow, increased cell division, disruption of the
basement membrane, and invasion of the surrounding stroma
(Fig. 1). Sim2/ mammary glands displayed several hallmarks
of EMT, including loss of E-cadherin, nuclear accumulation of
active -catenin, and increased expression of the invasion-
associated Mmp2 gene (Fig. 7). Together, these results suggest
that Sim2s plays an important role in establishing and/or main-
taining mammary cell fate.
Using an in vitro approach to knock down SIM2s expression
in human breast cancer cells, we established that SIM2s is also
a barrier to mammary cell transformation and tumor progres-
sion. The tumor-suppressive effects of SIM2s in mammary
epithelial cells appeared to depend, in part, on its ability to
suppress pathological EMT events initiated by SLUG (Fig. 6).
We have recently demonstrated that SIM2s is decreased in
human breast tumors and has tumor-suppressive activity when
reintroduced into highly invasive cancer cells (20). This hy-
pothesis is further supported by the data presented here.
Down-regulation of SIM2s in MCF-7 cells resulted in loss of
epithelial characteristics, increased invasion, and in vivo tu-
morigenesis. Furthermore, tumors arising from SIM2i MCF-7
cells developed rapidly and were ER and highly vascular-
ized (Fig. 3). Our present studies have also shed light on the
mechanistic basis of the tumor-suppressive properties of
SIM2s. We have demonstrated that SIM2s directly represses
transactivation of the SLUG and MMP promoters, which cor-
responds to elevated Slug and Mmp2 gene expression in
Sim2/ mammary epithelium (Fig. 6 and 7). To our knowl-
FIG. 6. SIM2s binds and represses expression from the SLUG promoter. (A) SLUG, but not SNAIL, mRNA levels were significantly reduced
following loss of SIM2s expression in MCF-7 cells. (B) Increased SLUG mRNA observed in SIM2i cells corresponded to significantly elevated
SLUG protein levels, as measured by Western blotting. (C) Expression of a SLUG promoter-controlled reporter was significantly increased in
SIM2i MCF-7 cells. The data are represented as means plus SEM; * indicates that P was 0.05. (D) SIM2s-mediated repression of SLUG is dose
dependent, as increasing amounts of SIM2s expression vector repressed expression of the SLUG reporter. The data are represented as means plus
SEM; ** indicates that P was 0.005. (E) Several putative regulatory regions are present in the first 3,280 bp of the SLUG promoter (top). ChIP
analysis using an antibody to SIM2 was used to ascertain SIM2s binding to the SLUG promoter in SCR and SIM2i MCF-7 cells. Precipitated
chromatin was assayed for the presence of SLUG promoter DNA surrounding a region containing a CME and multiple XRE consensus sequences
using primers as indicated by the arrows in the promoter schematic. SIM2s protein peaked in the center of this region and was detectable in this
region of the SLUG promoter in SCR control cells only. (F) SLUG and SIM2s binding to the E-cadherin promoter was analyzed in SCR and SIM2i
MCF-7 cells by ChIP analyses. A schematic representation of the human E-cadherin promoter from287 to55 with respect to the transcriptional
start point shows putative E-box, CCAAT enhancer binding protein, and SP1 regulatory regions, as well as the relative positions of primers used
to assay for protein binding. SLUG binding to the E-cadherin promoter was detectable in SIM2i cells, but not in SCR cells. In contrast, SIM2s
binding to the E-cadherin promoter could not be detected in either cell line.
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edge, these results make SIM2s the first known transcriptional
repressor of SLUG and suggest that SIM2s regulation of these
genes may be important for its tumor suppressor function in
vivo. We propose a model in which progressive loss of SIM2s
results in derepression of Slug and Mmp2, promoting E-cad-
herin loss, increased mitosis, angiogenesis, cell motility, and
invasiveness (Fig. 7B).
The morphological and biochemical changes observed in
SIM2 shRNA MCF-7 cells and Sim2/ mammary glands may
be interpreted as an EMT. However, there is fierce debate
about the relevance of EMT to human cancers, as EMT is
rarely observed in human tumor biopsies (19, 21, 39, 40). While
SIM2i cells ceased expressing epithelial markers and Sim2/
mammary epithelium displayed signs of EMT, neither ac-
quired the mesenchymal markers fibronectin and smooth mus-
cle actin (data not shown). Additionally, SIM2i MCF-7 cells
retained cell junctions that appeared to contain N- instead of
E-cadherin, and neither N-cadherin nor vimentin expression
was observed in Sim2/ mammary glands, which also ap-
peared to have intact cell-cell junctions (not shown). A possi-
ble explanation is that loss of SIM2s does indeed induce EMT
but that pathological EMTs are more heterogeneous in man-
ifestation than an EMT occurring during normal developmen-
tal processes. Another possibility is that SIM2i MCF-7 and
Sim2/ mammary epithelial cells are examples of the recently
proposed “metastable” phenotype (21). Savagner and others
have described the metastable phenotype as a fusion of epi-
thelial and mesenchymal characteristics within a single cancer
FIG. 7. Loss of Sim2s in the mouse mammary gland results in a phenotype consistent with EMT. (A) Analysis of mouse mammary outgrowths
from WT and Sim2/ mice revealed that loss of Sim2s expression is associated with EMT events, including loss of E-cadherin, up-regulation of
Mmp2, and increased activation of -catenin. Consistent with our hypothesis that Sim2s-mediated down-regulation of Slug represses EMT, we
found that Slug protein levels were significantly elevated in Sim2/ mammary glands. (B) Proposed model of Sim2 effects on mammary gland
ductal development and cancer. During normal mammary gland development, Sim2s is expressed in differentiated mammary epithelial cells lining
the ducts and alveoli, where it represses Slug, Mmp2, and possibly other factors promoting EMT and motility. During early transformation, Sim2s
expression is decreased, allowing Slug and Mmp2 expression to increase, leading to disruption of cell-to-cell contacts and degradation of the
surrounding extracellular matrix. As tumorigenesis progresses, Sim2s expression is lost and cancer cells become highly motile and aggressively
invade the surrounding stroma as metastasis is initiated.
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cell. Since SIM2s suppresses invasion-associated proteins
(MMPs) in addition to SLUG, it may be that loss of SIM2s
makes full EMT unnecessary for achieving optimal malig-
nancy. This is apparent when we compare SIM2i MCF-7 cells
grown in culture to those placed in the flanks of nude mice. In
culture, SIM2i MCF-7 cells displayed a mesenchymal morphol-
ogy not observed in SIM2i MCF-7 tumors. Similarly, the de-
grees of E-cadherin loss and N-cadherin and vimentin up-
regulation in SIM2i MCF-7 cells were much greater in culture
than in nude mice. Such observations are consistent with the
hypothesized epithelial-mesenchymal plasticity of metastable
cells and may explain how cells can rapidly metastasize without
displaying characteristics of a full-blown EMT. It is possible
that sufficient time had not passed to complete the full EMT
program in both SIM2i MCF-7 and Sim2/ mammary epi-
thelial cells. However, in light of how quickly SIM2i MCF-7
cells formed tumors, it is unlikely that complete EMT is nec-
essary to achieve the pathogenic effects of SIM2s loss. Indeed,
our data suggest that progressive reductions in SIM2s expres-
sion may transform epithelial cells and advance them rapidly
through progression to malignancy. While other studies have
implicated SIM2s as a tumor promoter (1, 9, 13), our present
and previous studies (20) point to a tumor suppressor role for
SIM2s. This suggests either that SIM2s has profoundly differ-
ent tissue-specific functions or that SIM2s can have both tu-
mor-suppressive and tumor-promoting effects depending upon
the cellular context. A similar mechanism has been shown to
govern the effects of transforming growth factor  in breast
cancer cells, which require a specific balance of CCAAT/en-
hancer binding protein  isoforms to inhibit the cell cycle (11).
These studies provide compelling new evidence that SIM2s
is required for proper mammary gland development and that it
is a mammary tumor suppressor gene. SIM2s appears to do
this, in part, by directly binding the SLUG promoter to repress
its expression (Fig. 6). In addition to regulating EMT, recent
evidence has shown that SLUG gene expression is associated
with basal-like breast carcinoma and is required for in vitro
expansion of ductal breast cancer stem/progenitor cells (35). If
so, it will be interesting to determine if SIM2s plays a role in
stem cell maintenance. Intriguingly, SLUG has also been im-
plicated in palate formation (25), and Sim2/ mice have pal-
ate abnormalities (29, 33), suggesting a connection between
SIM2 and SLUG in regulating palatogenesis, a process requir-
ing EMT. Potential associations between SIM2 and SLUG in
palatogenesis are also supported by the observation that facial
clefting is elevated in Down syndrome patients, who might be
expected to have higher levels of SIM2 due to trisomy 21 (18).
Intuitively, if SIM2s is a tumor suppressor, overexpression
would be antitumorigenic. This is supported by the observation
that individuals with Down syndrome are less susceptible to
solid tumors (2, 14–16, 31, 32) and that Down syndrome pro-
vides the highest known protection against breast cancer (2). In
light of our observations that SIM2s expression is lost in hu-
man breast cancers (20) and that loss of SIM2s promotes EMT
and tumorigenesis in human breast cancer cells, it is tempting
to speculate that increased expression of SIM2 is the root of
the increased incidence of palate defects and decreased risk for
solid tumors observed in Down syndrome patients (2, 14–16,
31, 32).
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